Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 12/21 cls
Alkermes (ALKS) Banc of America Securities William Ho New Buy 8% $15.86
Ho set an $18 target. He believes exenatide LAR to treat Type II diabetes is a potential blockbuster based on positive data from a 30-week, open-label trial presented by partner Amylin (AMLN) (see BioCentury, Nov. 5). He also expects Phase III data for inhaled AIR Insulin powder from ALKS and partner Eli Lilly (LLY) in 4Q08, with a potential launch in 2010.
Alnylam (ALNY) Broadpoint Simos Simeonidis New Buy -1% $29.92
Simeonidis set a $38 target. He believes RNAi "represents a potentially transformational technology" and that ALNY is a leader in the space.
Altus (ALTU) Collins Stewart Andrew Fein Downgrade Market perform (from buy) -47% $5.44
Fein downgraded the

Read the full 1357 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers